Pfizer CME effort lacks brand tie-in

Share this article:
Harvard affiliate Joslin Diabetes Center is mounting a CME research project with funding from a pharmaceutical company whose products are tangential to the therapeutic area.
It's uncommon for industry to fund CME without an aligned, proper commercial interest, and even more uncommon to fund research in CME. But Pfizer, which lacks a major product in diabetes, just committed a $300,000 challenge grant to the diabetes center to test the usefulness of different CME assessment methods, said Joslin executive director of professional education Julie Brown.
Pfizer has supported 50% of the grant as a challenge to other commercial supporters to step up and support the research, according to a statement issued by Joslin.
The firm's 2010 funding report lists $10,000 given in the fourth quarter as the “placeholder” for the full Pfizer commitment of $300,000, Brown said. The full grant will be awarded when it's fully funded through commitments from added supporters, which Brown is confident will be announced in the near future.
Why is Pfizer funding research in professional education without a clear product tie-in? “Pfizer recognizes the value of medical education,” said its chief medical officer Dr. Freda Lewis-Hall in the Joslin statement, adding that med ed can provide valuable information about treatment that may reduce the burden from chronic illness.
The firm eased up on metabolic R&D years ago after withdrawing Exubera, an inhaled insulin which never caught on in the marketplace. The closest drug in its portfolio would be Lyrica, approved for treating the pain of diabetic neuropathy, but the education and research has nothing to do with DPN, Brown said, adding that Pfizer's products are not relevant to the education that forms the basis for the research.
The goal is to analyze different outcomes methods that accredited CME providers use to measure performance of doctors.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: HealthSpot's teleconnected CEO

Headliner: HealthSpot's teleconnected CEO

Steve Cashman, Founder and CEO, HealthSpot

Recruitment: The New Breed

Recruitment: The New Breed

What do healthcare agencies really want when it comes to potential employees? The answer to that question is in a constant state of flux, as technologies, clients' changing demands and ...

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the September 2014 issue of MM&M, with all text, charts and pictures.